| 今开：6.3 | 昨收：6.15 |
| 最高：7.21 | 最低：6.2401 |
| 涨停价： | 跌停价： |
| 总市值：7.3697814E7 |
Lantern Pharma(LTRN)04-27 09:45
$Lantern Pharma(LTRN)$ 144 Report of proposed sale of securities Accession Number: 0001104659-24-053232 Act: 33 Size: 9 KB 网页链接查看全文
Lantern Pharma(LTRN)03-01 11:05
$Lantern Pharma(LTRN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-029534 Size: 41 KB 网页链接查看全文
Lantern Pharma(LTRN)03-02 05:15
$Lantern Pharma(LTRN)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001104659-24-029971 Act: 34 Size: 319 KB 网页链接查看全文
Lantern Pharma(LTRN)03-19 04:15
$Lantern Pharma(LTRN)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001493152-24-010302 Act: 34 Size: 9 MB 网页链接查看全文
Lantern Pharma(LTRN)04-29 19:35
$Lantern Pharma(LTRN)$ DEF 14A Other definitive proxy statements Accession Number: 0001493152-24-016840 Act: 34 Size: 924 KB 网页链接查看全文
Lantern Pharma(LTRN)04-27 09:45
$Lantern Pharma(LTRN)$ 144 Report of proposed sale of securities Accession Number: 0001104659-24-053229 Act: 33 Size: 9 KB 网页链接查看全文
Lantern Pharma(LTRN)03-01 11:05
$Lantern Pharma(LTRN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-029533 Size: 30 KB 网页链接查看全文
Lantern Pharma(LTRN)04-27 09:45
$Lantern Pharma(LTRN)$ 144 Report of proposed sale of securities Accession Number: 0001104659-24-053228 Act: 33 Size: 10 KB 网页链接查看全文
Lantern Pharma(LTRN)02-29 10:45
$Lantern Pharma(LTRN)$ 144 Report of proposed sale of securities Accession Number: 0001104659-24-028948 Act: 33 Size: 5 KB 网页链接查看全文
Lantern Pharma(LTRN)02-29 10:45
$Lantern Pharma(LTRN)$ 144 Report of proposed sale of securities Accession Number: 0001104659-24-028949 Act: 33 Size: 5 KB 网页链接查看全文
牛股小红书2022-01-13 10:55
$Lantern Pharma(LTRN)$ 宣布扩大与美国国立卫生研究院（National Institutes of Health）国家癌症研究所（NCI）的合作协议。
公司表示，这项合作的扩大是在确定了几个基因特征之后进行的，这些基因特征预测了患者肿瘤对Lantern的候选药物LP-184和LP-284的潜在反应。
LP-184作为一种新的...查看全文
$Lantern Pharma(LTRN)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001213900-21-055781 Act: 34 Size: 5 MB 网页链接
$Lantern Pharma(LTRN)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001213900-21-055780 Act: 34 Size: 3 MB 网页链接
$Lantern Pharma(LTRN)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001213900-21-039285 Act: 34 Size: 5 MB 网页链接
$Lantern Pharma(LTRN)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001213900-21-039286 Act: 34 Size: 4 MB 网页链接
$Lantern Pharma(LTRN)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-21-002727 Act: 33 Size: 1 KB 网页链接
$Lantern Pharma(LTRN)$ 8-K Current report, item 5.07 Accession Number: 0001213900-21-028984 Act: 34 Size: 37 KB 网页链接
$Lantern Pharma(LTRN)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001213900-21-024233 Act: 34 Size: 4 MB 网页链接
$Lantern Pharma(LTRN)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001213900-21-024222 Act: 34 Size: 1 MB 网页链接
$Lantern Pharma(LTRN)$ DEF 14A Other definitive proxy statements Accession Number: 0001213900-21-020952 Act: 34 Size: 2 MB 网页链接
$Lantern Pharma(LTRN)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001213900-21-020953 Act: 34 Size: 431 KB 网页链接